Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2487-2493

  Puglisi, Fabio ^a,d   Mansutti, Mauro ^b   Aprile, Giuseppe ^a   Minisini, Alessandro Marco ^a   Di Loreto, Carla ^a   Bazzocchi, Massimo ^a   Londero, Viviana ^a   Cedolini, Carla ^a   Gentile, Giuliana ^b   Pizzolitto, Stefano ^b   Piga, Andrea ^a   Sobrero, Alberto ^c  

^a UNIVERSITY OF UDINE   (Italy)

^b GENERAL HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Breast cancer; Cyclophosphamide; Docetaxel; Doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PREDNISONE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEMOSENSITIVITY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYPERSENSITIVITY; IMAGING; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PREOPERATIVE CARE; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS;

EID: 4444270896     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T and Senn H: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608, 2003.
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-85, 1998.
3. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P and Bonadonna G, for the ECTO Study Group: First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on loco-regional disease. Proc Am Soc Clin Oncol 21: 34a, (Abstract 132), 2002.
4. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19: 4224-4237, 2001.
5. Jakesz R, for the ABCSG: Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 20: 32a, (Abstract 125), 2001.
6. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y and Durand JC: Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 30A: 645-652, 1994.
7. Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R and Filipits M: Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78: 97-103, 2003.
8. Smith IE and Lipton L: Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncology 2: 561-570, 2001.
9. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S and van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406-412, 2003.
10. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
11. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP and Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
12. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A and Aapro M, 304 Study Group: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424, 1999.
13. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M and Riva A: Prospective randomized trial of docetaxel vs doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999.
14. ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J and Alakl M: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5: 527-532, 1994.
15. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
16. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU and Hortobagyi GN: Phase II trials of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995.
17. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C and Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21: 36a, (Abstract 141), 2002.
18. De Laurentiis M: Sequential epirubicin-docetaxel-CMF regimen as adjuvant therapy of early breast cancer: Preliminary results of the Taxit-216 multicenter phase III trial. Proc Am Soc Clin Oncol 22: 29, (Abstract 115), 2003.
19. Gogas H and Fountzilas G: The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 14: 667-674, 2003.
20. Hutcheon AW, Heys SD, Sarkar TK, and the Aberdeen Breast Group: Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 79(Suppl. 1): S19-S24, 2003.
21. Snead DR, Bell JA, Dixon AR, Nicholson RI, Elston CW, Blamey RW and Ellis IO: Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 23: 233-8, 1993.
22. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-10, 1991.
23. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU and Hortobagyi GN: Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20: 17-23, 2002.
24. Padhani AR and Ollivier L: The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986, 2001.
25. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J and Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a high pathologic response and breast-conservation rate. Br J Cancer 88: 1339-1345, 2003.
26. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R and Sledge GW Jr: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of Hoosier Oncology Group. J Clin Oncol 17: 3033-3037, 1999.
27. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM and Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47: 3889-94, 1987.
28. Aapro M: Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Semin Oncol 25(Suppl 12): 7-11, 1998.
29. Luporsi E, Vanlemmens L, Coudert B, Mayer F, Bonneterre J, Petit T, Borel C, Hirsch M and Bey P: 6 cycles of FEC 100 vs 6 cycles of Epirubicin-Docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): preliminary results of a randomized phase II trial of Girec S01. Proc Am Soc Clin Oncol 19: 92a, (Abstract 355), 2000.
30. Smith IE, A'Hern R, Coombes G, Hickish T, O'Brien M, Robinson A, Laing R, Hong A, Verrill M and Wardley A, for the TOPIC Trialists Group: A randomised neoadjuvant chemotherapy trial of vinorelbine/epirubicin (VE) vs standard doxorubicin/cyclophosphamide (DC) in patients with >3cm diameter operable breast cancer (TOPIC 2). Proc Am Soc Clin Oncol 22: 21, (Abstract 83), 2003.
31. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL and Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
32. Von Minckwitz G, Raab G, Schuette M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe W, Jackisch C, duBois A, Caputo A and Kaufmann M: Dose-dense versus sequential adriamcycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2,M0) - primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 21: 43a, (Abstract 168), 2002.